AlloHSCT – Medxy AI

Evolving GVHD Prophylaxis in AlloHSCT: Insights from a Large Real-World Spanish Cohort

By MedXY 09/22/2026

A large Spanish study reveals the shifting landscape of GVHD prophylaxis in alloHSCT, highlighting widespread post-transplant cyclophosphamide use and its impact on acute and chronic GVHD incidence and survival outcomes.

Hematology-Oncology news

Blinatumomab Consolidation in High-Risk Ph-Negative B-Cell Acute Lymphoblastic Leukemia: Insights from the GRAALL-2014/B-QUEST Study

By MedXY 07/20/2026

The GRAALL-2014/B-QUEST study demonstrates that integrating blinatumomab into consolidation and maintenance therapy significantly improves outcomes for adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Clinical Updates Hematology-Oncology news

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results

By MedXY 03/19/2026

This review analyzes the Phase 3 Precision-T trial, demonstrating that Orca-T, a high-precision T-cell therapy, significantly improves chronic GVHD-free survival and reduces non-relapse mortality compared to standard-of-care prophylaxis in patients with hematologic malignancies.